Pulmonary interstitial pneumonia treatment
US10052336B2 · kind B2 · utility
Inventor
Key dates
| Filing date | Feb 9, 2017 |
| Grant date | Aug 21, 2018 |
| Priority date | — |
| Expiry date | Feb 9, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/616
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Model and method of treating inflammatory diseases. Traditional treatments for such diseases include administering to the patient toxic anti-inflammatory drugs. Following stabilization of the symptoms, the drug doses are tapered down to minimize side effects, as a result of which inflammation remains high and the disease is rarely cured. A chemistry-based disease model concludes that irrespective of the role that inflammation plays in the disease, inflammation reduction will impede disease initiation and progression. Managing and controlling inflammatory diseases requires reducing inflammation to acceptable normal values. Non-toxic ways such as non-steroidal anti-inflammatory drugs, anti-inflammatory diets, and regular exercise allow such reduction in inflammation to normal values, thereby slowing down or arresting disease progression and allowing the discontinuation or reduction of toxic anti-inflammatory therapy while maintaining low inflammation using non-toxic therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.